Hallucinations Archives

Acadia Resubmits Nuplazid for Expansion into Dementia-Related Psychosis

5-HT2A receptor inverse agonists, BioSpace, Delusions, FDA, Hallucinations, Neuropsychiatric Diseases, Parkinson’s Disease Psychosis, Primary Endpoints, R&D, Supplemental New Drug Application (sNDA)

Less than a year after a regulatory setback, Acadia Pharmaceuticals resubmitted the company’s supplemental New Drug Application for Nuplazid (pimavanserin) as a potential treatment for hallucinations and delusions associated with dementia-related psychosis.

February 17, 2022/by BioSpace

Acadia’s Nuplazid Receives FDA CRL for Dementia-Related Psychosis

Clinical Trial Endpoints, Clinical Trials, Complete Response Letter, Delusions, Hallucinations, Primary Endpoints, R&D, Secondary Endpoints, Therapeutics

The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) over Acadia Pharmaceuticals’ supplemental New Drug Application (sNDA) for Nuplazid for hallucinations and delusions associated with dementia-related psychosis.

April 5, 2021/by Andrew Humphreys